Pharmaceutical composition comprising sclerostin inhibitor as active ingredient for prevention or treatment of diabetic eye disease

Abstract

The present invention relates to a pharmaceutical composition comprising a sclerostin inhibitor as an active ingredient for the prevention or treatment of diabetic eye disease, wherein the composition, by inhibiting sclerostin, not only reduces the expression levels of inflammatory cytokines significantly even under conditions of VEGF treatment and hyperglycemia, thereby exhibiting an excellent anti-inflammatory activity, but also is shown to have a significant angiogenic effect due to reduced expression of vascular adhesion markers and vascular endothelial growth factors, thereby inhibiting the principal characteristic of diabetic eye disease, the inflammatory response, and microvascular complications. In addition, the composition reduces oxidative stress caused by diabetes and does not induce cell death and thus can be useful as a preparation for the prevention or treatment of diabetic eye disease.

Dependencies are inferred from the claim text.